Stockscreener 앱 받기
15.16
9.86%
1.36
시장 영업 전:
15.65
0.49
+3.23%
전일 마감가:
$13.80
열려 있는:
$15.07
하루 거래량:
404.45K
Relative Volume:
4.19
시가총액:
$818.40M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.81%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$13.90
$15.66
1주일 범위
$13.39
$15.66
52주 변동 폭
$13.29
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Compare EIKN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
15.16 | 744.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eikon Therapeutics Inc 주식(EIKN)의 최신 뉴스
Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan
Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada
BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia
BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com
This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com
BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa
Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com
Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com India
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com
JPMorgan initiates Eikon Therapeutics stock at Overweight - Investing.com
Bank of America Global Research recently announced the official initiation of research coverage on biotechnology company Eikon Therapeutics (stock code: EIKN), and assigned an initial "Buy" rating. - Bitget
Bay Area life sciences firms raise $6.1B as three companies go public - The Business Journals
Eikon Therapeutics, Inc.Common Stock (NQ: EIKN - The Chronicle-Journal
Eikon Therapeutics, Inc.: Dividend historical data and projections - marketscreener.com
Eikon Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | EIKN | US2825641036 - marketscreener.com
IPO Tracker 2026: Generate Clocks Largest IPO Since 2024 With $400M Raise - BioSpace
Eikon Therapeutics stock drops after Wedbush downgrade - Investing.com
Eikon Therapeutics stock drops after Wedbush downgrade By Investing.com - Investing.com India
Wedbush initiates Eikon Therapeutics stock with underperform rating By Investing.com - Investing.com Australia
Wedbush initiates Eikon Therapeutics stock with underperform rating - Investing.com
What is the current Price Target and Forecast for Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
Eikon Therapeutics Prices $381 Million Initial Public Offering - Global Legal Chronicle
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga
EIKN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTAQ
It was supposed to be the biggest week for IPOs in years. But a 'selective' market didn't cooperate - The Business Journals
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com
Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials - MedCity News
Covington, Davis Polk Lead Eikon's Upsized $381M IPO - Law360
Eikon Therapeutics Shares Fall in Nasdaq Debut - marketscreener.com
Eikon IPO grows to biggest for biotech since 2024, raising nearly $400 million before stock falls in debut - The Business Journals
Eikon Therapeutics Opens At $17.05, IPO Priced At $18 By Investing.com - Investing.com Canada
Eikon’s $381M raise represents largest biopharma IPO in two years - bioworld.com
Eikon Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Eikon Therapeutics, Inc. share price - Capital.com
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com India
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO - 1470 & 100.3 WMBD
Eikon Therapeutics raises $381M in IPO - Axios
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings - BioPharma Dive
Eikon Therapeutics prices upsized IPO at $18 per share - Investing.com Australia
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com
Eikon Therapeutics Inc (EIKN) 재무 분석
Eikon Therapeutics Inc (EIKN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):